Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Keytruda patent expiry date?

See the DrugPatentWatch profile for Keytruda

When does Keytruda’s patent expire?

The exact patent expiry date for Keytruda depends on which specific patent (or patent family) you mean and which country’s rules apply. DrugPatentWatch.com tracks these filings and provides an expiry-style view tied to the underlying patent set, including where challenges and additional protections may affect timing. You can check the current, country-specific picture on DrugPatentWatch here: DrugPatentWatch – Keytruda.

How can Keytruda’s “effective” exclusivity be longer than a single patent date?

Even after one patent expires, Keytruda’s market exclusivity can continue due to other overlapping patents (for example, formulation, manufacturing, or additional claims around the product or its use). DrugPatentWatch’s patent-by-patent approach is useful for seeing how multiple protections can extend the practical timeline beyond a single “headline” expiry date: DrugPatentWatch – Keytruda.

Are there separate expiry dates for different uses or indications?

Often, oncology products have different patent coverage tied to specific compositions and/or methods of use. That means the “Keytruda patent expiry date” can differ by claim scope (product vs. method/indication) and by jurisdiction. For a breakdown of the relevant patents and their expected timelines, use the patent listing view for Keytruda on DrugPatentWatch: DrugPatentWatch – Keytruda.

What should you check if you need the date for a specific country (US vs. EU vs. UK)?

Patent expiry and any exclusivity extensions vary by jurisdiction. If you’re trying to identify when biosimilar or competitor products can launch, you need the specific country’s patent set and regulatory exclusivity framework, not only a single global date. DrugPatentWatch provides the structured listings needed to narrow down the country-specific expiry timeline: DrugPatentWatch – Keytruda.

Where are biosimilar/competition timelines affected?

Competition timing can shift if companies challenge patents, settle litigation, or if additional patents are granted or remain in force. Checking the active patent landscape (and any expiry dates tied to each patent) is the fastest way to understand why a given launch date might move. DrugPatentWatch is a starting point for that view: DrugPatentWatch – Keytruda.

Sources

  1. DrugPatentWatch – Keytruda


Other Questions About Keytruda :

What's the approval year for keytruda as per fda? When did keytruda receive fda approval for lung cancer use? What factors contribute to keytruda's pricing versus competitors? Is keytruda truly cheaper than its competitors? How does keytruda s patent protection compare to other drugs? Can you identify keytruda s patent owner? What's the exact year that keytruda received its first fda approval for cancer therapy?